The effect of shortening the atrioventricular (AV) interval on blood pressure management in patients with atrioventricular block (AVB) and hypertension.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500107165

Enrollment

Unknown

Registered

2025-08-05

Start date

2025-08-31

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1.Patients who have undergone dual-chamber pacemaker implantation for second-degree type II or third-degree atrioventricular block (AVB) with an anticipated pacing percentage >40%. 2.Patients with a documented history of hypertension and office-measured systolic blood pressure =130 mmHg.

Interventions

Control group:AV interval set to PAV/SAV:200/180ms

Test group:AV interval set to PAV/SAV: 120/100ms

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Age Range (18–85 Years); 2. Second-Degree Type II or Third-Degree AVB with Expected Pacing Proportion >40%; 3. Conduction System Pacing (CSP) for Dual-Chamber Pacemaker Implantation; 4. Hypertension History with Office Systolic Blood Pressure (SBP) >=130 mmHg; 5. Able and willing to provide written informed consent, comply with all study procedures (including follow-up visits), and share relevant medical and device data for research purposes.

Exclusion criteria

Exclusion criteria: 1. Systolic blood pressure >180 mmHg; 2. Secondary hypertension with a confirmed etiology; 3. History of heart failure, including HFrEF and HFmrEF; 4. History of paroxysmal or persistent atrial fibrillation; 5. History of structural heart disease, including hypertrophic cardiomyopathy, restrictive cardiomyopathy, or other cardiomyopathies; 6. History of cardiac surgery within the past 6 months; 7. History of renal disease or renal artery disease; 8. Known carotid artery disease; 9. Contraindications to pacemaker implantation (e.g., active infections); 10. Pregnant women or those planning pregnancy during the study period; 11. Participation in other clinical trials that may interfere with the execution or outcome analysis of this study;

Design outcomes

Primary

Measure	Time frame
Systolic blood pressure control rate post-randomization;	—

Secondary

Measure	Time frame
Left ventricular ejection fraction;6-minute Walk Test;	—

Countries

China

Contacts

Public ContactWang Haixong

Shanxi Cardiovascular Hospital

cz1976whx@126.com+86 351 566 1233

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026